Top entities: Phathom Pharmaceuticals, Levi & Korsinsky, Steve Basta, Sanjeev Narula, Joseph E. Levi.

What category does this event fall under?

Business — classified as guidance cut.

What is the sentiment of coverage?

Aggregate sentiment score: -30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Phathom Pharmaceuticals cut revenue guidance · Levi & Korsinsky commenced investigation Phathom Pharmaceuticals

Is this event still developing?

This is an active story, last updated Aug 03, 2026. Coverage continues to evolve.

Business guidance cut

Phathom cuts 2026 revenue guidance

Q: When did this event occur?

First reported Jul 30, 2026; last updated Aug 03, 2026.

Q: What is the market impact?

General. The guidance cut signals weaker-than-expected commercial performance for Phathom's key product, likely pressuring the stock price and investor sentiment.

Analysis based on 9 articles · First reported Jul 30, 2026 · Last updated Aug 03, 2026

Sentiment

-30

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The guidance cut signals weaker-than-expected commercial performance for Phathom's key product, likely pressuring the stock price and investor sentiment. The securities investigation adds legal and reputational risk, potentially further impacting the company's market valuation.

Pharmaceuticals

Event Summary

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reduced its full-year 2026 revenue guidance to $300 million-$325 million from the previously reaffirmed $320 million-$345 million range, removing $20 million from both ends of the outlook. The revised guidance fell below Wall Street consensus estimates of approximately $332 million-$334 million. The company's revenue is concentrated in a single approved product, VOQUEZNA (vonoprazan), and the reduction reflects a weaker commercial ramp. Management had reaffirmed the original guidance on the April 30, 2026 Q1 earnings call, with CEO Steve Basta and CFO Sanjeev Narula citing continued growth and a commercial build of more than 290 sales representatives. Following the guidance cut, PHAT shares declined, and Levi & Korsinsky, LLP commenced an investigation into potential securities law violations on behalf of investors who suffered losses.

Key Actions

100 Phathom Pharmaceuticals cut revenue guidance

80 Levi & Korsinsky commenced investigation Phathom Pharmaceuticals

Entities Involved

stock

Phathom Pharmaceuticals

Phathom Pharmaceuticals is the central entity; it cut its FY 2026 revenue guidance, causing a share decline and triggering a securities investigation. The company's valuation is heavily dependent on the commercial ramp of VOQUEZNA.

Importance 100.0 Sentiment -40.0

priv

Levi & Korsinsky

Levi & Korsinsky is the law firm that commenced the investigation into Phathom Pharmaceuticals for potential securities law violations. The firm is acting on behalf of investors who suffered losses.

Importance 60.0 Sentiment 0.0

per

Steve Basta

Steve Basta is the President and CEO of Phathom Pharmaceuticals. He reaffirmed the original revenue guidance on earnings calls, and his statements are part of the investigation into potentially misleading disclosures.

Importance 40.0 Sentiment -20.0

per

Sanjeev Narula

Sanjeev Narula is the CFO of Phathom Pharmaceuticals. He also reaffirmed the revenue guidance and provided details on gross-to-net discounts, contributing to the context of the guidance cut.

Importance 30.0 Sentiment -20.0

per

Joseph E. Levi

Joseph E. Levi is a partner at Levi & Korsinsky and the contact for investors seeking to participate in the investigation. His role is to represent shareholders in potential securities litigation.

Importance 20.0 Sentiment 0.0

Relationships

Levi & Korsinsky related ↔ Joseph E. Levi

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard